Antimicrobial Drug News and Research

RSS

Antimicrobials are substance that kills microorganisms such as bacteria or mold, or stops them from growing and causing disease.

Powerful database focuses on disarming deadly superbugs

Disarming superbugs that can cause deadly infections is the focus of a powerful database now housed at The University of Queensland.

21 Nov 2021

Study finds FDA-approved drug has potent antiviral activity against SARS-CoV-2 and variants of concern

A new study aimed to examine the antiviral potential of atovaquone against the original SARS-CoV-2 strain and other variants of concern.

25 Oct 2021

New molecule extracted from the leaves of chestnut tree neutralizes staph bacteria

Scientists isolated a molecule, extracted from the leaves of the European chestnut tree, with the power to neutralize dangerous, drug-resistant staph bacteria. Frontiers in Pharmacology published the finding, led by scientists at Emory University.

28 Jun 2021

A new strategy to combat pathogenic bacterium

Pseudomonas aeruginosa is an opportunistic pathogenic bacterium present in many ecological niches, such as plant roots, stagnant water or even the pipes of our homes. Naturally very versatile, it can cause acute and chronic infections that are potentially fatal for people with weakened immune systems.

21 Jun 2021

International travelers often return home with new bacterial strains, confirms study

Carried like stowaways in the guts of international travelers, new and potentially deadly strains of antimicrobial resistant superbugs may be coming to a community near you, suggests new research from Washington University School of Medicine in St. Louis.

7 Jun 2021

Pseudomonas aeruginosa poses a serious threat to human health

No one knows exactly when humans and pathogenic bacteria were encountered with each other. But since then, the war began over life and survival between them. During this time, both sides of the war tried to equip themselves with all their might.

2 Jun 2021

ATS publishes new clinical practice guideline on community-acquired pneumonia

In its latest clinical practice guideline on community-acquired pneumonia the American Thoracic Society's guidelines panel addresses the use of nucleic acid-based testing for non-influenza viral pathogens.

4 May 2021

Discovery of new killing mechanism could help design improved teixobactin-based drugs

Scientists at the University of Liverpool and University of Utrecht have taken another step forward on their quest to develop a viable drug based on teixobactin - a new class of potent natural antibiotic capable of killing superbugs.

5 Jun 2020

Study: Bangladesh’s surface waters have high levels of antibiotic residues, chemicals

High levels of antibiotic residues, other medicines and chemicals present in Bangladesh's ponds, canals, lakes, rivers and other surface waters are contributing to a spike in antibiotic resistance in the country, says a new study.

11 Apr 2020

Metal complexes could hold the key to next generation of antibiotics

Compounds containing metals could hold the key to the next generation of antibiotics to combat the growing threat of global antibiotic resistance.

27 Feb 2020

Research provides new options for treatment of multi-drug resistant infections

A new study, published in 'Antimicrobial Agents and Chemotherapy' conducted by a University of Liverpool led research consortium, has helped develop a new treatment option for some multi-drug resistant infections.

30 May 2019

New research identifies novel link between antibiotic resistance and climate change

New research presented at this week's 29th European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam, Netherlands, identifies a novel association between antibiotic resistance and climate change.

15 Apr 2019

GARDP forms multi-actor partnerships to discover new antibiotics

Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization's priority pathogens The Global Antibiotic Research and Development Partnership is partnering with Calibr, the Helmholtz Centre for Infection Research, in particular its location Helmholtz-Institute for Pharmaceutical Research Saarland, and the University of Queensland's Community for Open Antimicrobial Drug Discovery in its efforts to develop and ensure new antibiotics are globally available to all patients who need them.

11 Apr 2019

GARDP and Evotec partner to tackle growing threat of antimicrobial resistance

The Global Antibiotic Research and Development Partnership and Evotec AG are today announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance.

19 Mar 2019

Study provides evidence of beta lactamase producing, antimicrobial resistant E. coli in U.S. retail meat

A new study using antimicrobial susceptibility testing and whole genome sequencing to test extended spectrum beta lactamase producing E. coli isolated from cattle for food production and from various retail meat products has shown that all were resistant to at least three antimicrobial classes.

24 Sep 2018

Wound healing work presented at the RCP Innovation in Medicine Conference 2018 by Neem Biotech

Neem Biotech recently attended the Royal College of Physicians’ Innovation in Medicine Conference 2018 where Neem presented their data around wound-relevant biofilms.

From Neem Biotech 23 Aug 2018

Award granted to Neem Biotech to develop antimicrobial intervention for chronic lung infections

Neem are working on a novel approach to antimicrobial resistance, which involves preventing the formation of and disrupts mature biofilms that are produced by bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus.

From Neem Biotech 18 Jun 2018

Discovery holds potential to pave way for new synergistic drug combinations

New data from a study led by researchers from the University of Minnesota Medical School could change how future antimicrobial drug combinations are discovered and developed.

27 Mar 2018

Neem Biotech to share findings on cystic fibrosis biofilm disruption at ECFS Basic Science Conference

Neem Biotech, a Wales-based R&D biotech working in the field of novel antimicrobial drug development, announced today that it will be presenting results of its ongoing development work into the impact of NX-AS-401, its lead candidate,on biofilms in chronic cystic fibrosis lung infections at the 15th European Cystic Fibrosis Basic Science Conference taking place from 21st to 24th March 2018 in LoutrakiKorinthias, Greece.

From Neem Biotech 22 Mar 2018

New class of antimicrobial polymers can kill five hard-to-treat multidrug-resistant bacteria

An international research team led by the Institute of Bioengineering and Nanotechnology of the Agency for Science, Technology and Research and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects.

7 Mar 2018